RxDoctor Payments Data

Trevor Rohm, MD

Family Medicine · Hereford, TXNPI 1780723791

Payments from drug & device makers

$410in general payments, 2019–2025

Across 24 payments — averaging $17.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$73
  • Astellas Pharma US Inc$67
  • GSK$44
  • Teva Pharmaceuticals USA, Inc.$38
  • Pfizer$33
  • Philips North America LLC$26
  • plus $129 from 7 others

What the payments were for

  • Food & beverage$39195%
  • Education$195%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$410 in reported general payments places this provider in the 45th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$29,160
Medicare patients
87
Services billed
374

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide126$129,328
EliquisApixaban182$84,975
JardianceEmpagliflozin91$83,594
TrulicityDulaglutide35$44,680
MounjaroTirzepatide26$35,994
JanuviaSitagliptin Phosphate34$32,333
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$24,795
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog56$24,481
EntrestoSacubitril/Valsartan32$22,210
FarxigaDapagliflozin Propanediol24$21,484
XareltoRivaroxaban27$19,349
Tresiba Flextouch U-100Insulin Degludec21$15,643
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog11$14,997
ShingrixVaricella-Zoster Ge/As01b/Pf66$13,796
AbrysvoRsv Vacc, Pref A And Pref B/Pf41$12,135

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$18$129,328126 claims
PfizerEliquis, Abrysvo$33$97,111223 claims
Boehringer IngelheimJardiance$19$83,59491 claims
GSKTrelegy Ellipta, Shingrix, Arexvy, Anoro Ellipta, Breo Ellipta$44$66,211174 claims
AstraZenecaFarxiga, Breztri Aerosphere, Brilinta$19$35,43852 claims
AbbVieLinzess$73$11,26021 claims
Astellas Pharma US IncMyrbetriq$67$3,56618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Hereford

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →